SBIR/STTR Research Award

Unique Antimicrobial Vascular Catheter to Prevent Catheter-Related Blood Stream Infections (CRBSI)

Award identifier 47227419d6a2cf8044845acf501827424de8f0a92065d43a1113c758f5217c7bAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$272,702

Program and phase

SBIR · Phase I

Award year

2023

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Brighton Development
Proposal award date
2023-09-01
Contract end date
2024-02-29
UEI
RYCEB8HU2U77
Solicitation number
PA22-176
Topic code
NHLBI

Research abstract

Abstract The goal of this Phase I effort is determine the feasibility of developing a unique antimicrobial catheter to reduce the instances of one of the most prevalent healthcare associated infection, Catheter-Related Blood Stream Infection (CRBSI). This research and development effort will be to develop an intravascular catheter with inherent long lasting antiseptic properties to protect the patient and prevent infection. The proposed device is a new approach to antimicrobial catheters. It will use common vascular catheter designs and materials, with the addition of an antimicrobial polymer additive to the elastomer to render the catheter antimicrobial. The unique additive replaces a portion of the silica reinforcing filler in the elastomer and is designed to provide the antibacterial agent to produce a permanent antimicrobial catheter surface. This innovation is based on the development of an antimicrobial polymer that has self- sterilizing properties that results in greater than six log kill of microorganisms inoculated onto the surface. The additive filled elastomer used for the catheter shaft has been tested against 10 common heath-care associated pathogens and has demonstrated a greater than six log kill (99.9999%) in 2 hrs at body temperature. The antimicrobial elastomer has also been demonstrated to be biocompatible passing a battery of tests. In this Phase I research we will expand the biocompatibility testing to evaluate the antimicrobial elastomer for suitability as an intravascular catheter. Both the connecting hub and the catheter tubing will have antimicrobial properties that will stop the primary access points for pathogens to the bloodstream. The catheter can be manufactured inexpensively with standard medical tubing manufacturing processes and materials, but will have the value-added property of antimicrobial activity. A durable and effective antimicrobial vascular catheter that can prevent or reduce CRBSI will save millions of dollars in healthcare cost and thousands of lives annually.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

11 SBIR/STTR records share this UEI (2003–2023). Reported award amounts total $5,205,139. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.